Medicis Pharmaceutical — Merger or Acquisition (September 2012)
17 slides from Medicis Pharmaceutical's merger presentation, Sep 5, 2012
Slide 1: Communication Plan
Communication Plan Exhibit 99.2
Slide 2: Who is Valeant?
Who is Valeant?
Slide 3: Valeant Overview
Valeant Overview Focused, multinational specialty pharma company $2.4B in 2011 revenue and ~7,000 employees Headquartered in Montreal, Canada (NYSE/TSX: VRX) International footprint Specialty Pharma (U.S., Canada, Australia, New Zealand) Branded Generics – Central and Eastern Europe; Latin America;
Slide 4: Highly Complementary Dermatology Portfolio
Highly Complementary Dermatology Portfolio Topical Acne Oral Acne Actinic Keratosis Dermatitis OTC Anti-Viral Anti-Fungal Single Agent Imiquimod Product 5FU Product Non-Steroidal Steroidal Combination Agent
Slide 5: Complementary Aesthetic Portfolio
Complementary Aesthetic Portfolio Collagen Stimulator Dermal Filler Botulinium Toxin Physician dispensed
Slide 6: Comprehensive Late Stage Pipeline
Comprehensive Late Stage Pipeline Late Stage Pipeline Medicis Novel LCM Aesthetics Dermatitis A. Keratosis Acne Anti-Fungal OTC
Slide 7: Valeant Pipeline
Valeant Pipeline
Slide 8: Valeant-Financial Information
Valeant-Financial Information
Slide 9: Talking Points by Audience
Talking Points by Audience
Slide 10: Audiences
Audiences Employees Headquarters Commercial team Investors Physicians Alliance Partners Vendors
Slide 11: Employee Talking Points JS & CCOM
Employee Talking Points JS & CCOM Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-in-cl
Slide 12: Employee Talking Points Field Sales
Employee Talking Points Field Sales VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-in-class commercial and R&D operations, and serve the consu
Slide 13: Jonah's Voicemail Script
Jonah’s Voicemail Script Good morning. This is Jonah Shacknai, Chairman and CEO and I have some important news to share with you. Just minutes ago, Medicis announced the signing of a merger agreement where Valeant Pharmaceuticals would acquire Medicis, creating a combined company that will be a glob
Slide 14: Investors
Investors Talking points for IR teams Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share The combination of our two highly complementary product portfolios under the Medicis name will allow us to accelerate our efforts to drive sales, establish best-i
Slide 15: Physicians
Physicians Talking points for the commercial team VRX to Merge with Medicis Combined commercial operations, as Medicis, will be located in Scottsdale, AZ This combination of two highly complementary product portfolios under the Medicis name will allow us to better serve medical and aesthetic dermato
Slide 16: Alliance Partners
Alliance Partners Terms of the transaction signed on Sunday September 2nd VRX to Merge with Medicis for $44 per share Combined commercial operations will be located in Scottsdale, AZ R&D will be in Scottsdale and Petaluma (No. California) Corporate functions will be located in NJ Will take time to o
Slide 17: Vendors
Vendors Dear XXXX, Medicis announced on September 3, 2012 its intent to combine with Valeant Pharmaceuticals International, Inc. (“Valeant”). As currently contemplated by the parties, the combined commercial operations, as Medicis, will be located in Scottsdale, AZ. After closing, the combined entit
Medicis Pharmaceutical — Merger or Acquisition (September 2012) on 6ix